Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption

Pharmacogenetics and Genomics

Volumn 24, Issue 3, 2014, Pages 172-176

  Chenoweth, Meghan J ^a   Zhu, Andy Z X ^a   Sanderson Cox, Lisa ^b   Ahluwalia, Jasjit S ^c   Benowitz, Neal L ^d   Tyndale, Rachel F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

African Americans; Genetic association studies; Metabolism; Nicotine; Smoking; Tobacco

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 3A; CYTOCHROME P450 REDUCTASE; DIMETHYLANILINE MONOOXYGENASE; NICOTINE;

AFRICAN AMERICAN; ALLELE; ARTICLE; CAUCASIAN; ENZYME ACTIVITY; ENZYME METABOLISM; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NICOTINE METABOLISM; PRIORITY JOURNAL; SMOKING; XENOBIOTIC METABOLISM;

NICOTIANA TABACUM;

AFRICAN CONTINENTAL ANCESTRY GROUP; ARYL HYDROCARBON HYDROXYLASES; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GENOTYPE; HUMANS; METABOLIC CLEARANCE RATE; NADPH-FERRIHEMOPROTEIN REDUCTASE; NICOTINE; OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING;

EID: 84894078170     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000031     Document Type: Article

References (12)

1. St Helen G, Dempsey D, Wilson M, Jacob P 3rd, Benowitz NL. Racial differences in the relationship between tobacco dependence and nicotine and carcinogen exposure. Addiction 2013; 108:607-617
2. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004; 14:615-626
3. Mwenifumbo JC, Al Koudsi N, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, et al. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat 2008; 29:679-688
4. Al Koudsi N, Ahluwalia JS, Lin SK, Sellers EM, Tyndale RF. A novel CYP2A6 allele (CYP2A6 35) resulting in an amino-Acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics J 2009; 9:274-282
5. Bloom AJ, Murphy SE, Martinez M, von Weymarn LB, Bierut LJ, Goate A. Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption. Pharmacogenet Genomics 2013; 23:62-68
6. Hisamuddin IM, Yang VW. Genetic polymorphisms of human flavincontaining monooxygenase 3: Implications for drug metabolism and clinical perspectives. Pharmacogenomics 2007; 8:635-643
7. Hu L, Zhuo W, He YJ, Zhou HH, Fan L. Pharmacogenetics of P450 oxidoreductase: Implications in drug metabolism and therapy. Pharmacogenet Genomics 2012; 22:812-819
8. Mwenifumbo JC, Sellers EM, Tyndale RF. Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking. Drug Alcohol Depend 2007; 89:24-33
9. Cox LS, Nollen NL, Mayo MS, Ws Choi, Faseru B, Benowitz NL, et al. Bupropion for smoking cessation in African American light smokers: A randomized controlled trial. J Natl Cancer Inst 2012; 104: 290-298
10. Al Koudsi N, Hoffmann EB, Assadzadeh A, Tyndale RF. Hepatic CYP2A6 levels and nicotine metabolism: Impact of genetic, physiological, environmental, and epigenetic factors. Eur J Clin Pharmacol 2010; 66:239-251
11. Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, et al. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: Multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 2009; 10:579-599
12. Hinrichs AL, Murphy SE, Wang JC, Saccone S, Saccone N, Steinbach JH, et al. Common polymorphisms in FMO1 are associated with nicotine dependence. Pharmacogenet Genomics 2011; 21:397-402